These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 19380407

  • 1. PET/CT for therapy response assessment in lymphoma.
    Hutchings M, Barrington SF.
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [Abstract] [Full Text] [Related]

  • 2. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
    Kasamon YL, Jones RJ, Wahl RL.
    J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
    [Abstract] [Full Text] [Related]

  • 3. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ, Herrmann K, Wieder H, zum Büschenfelde CM.
    J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [Abstract] [Full Text] [Related]

  • 4. Use of PET/CT to evaluate response to therapy in lymphoma.
    Zanoni L, Cerci JJ, Fanti S.
    Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):633-47. PubMed ID: 22231583
    [Abstract] [Full Text] [Related]

  • 5. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma.
    Karantanis D, O'Neill BP, Subramaniam RM, Peller PJ, Witte RJ, Mullan BP, Wiseman GA.
    Clin Nucl Med; 2007 Apr; 32(4):271-4. PubMed ID: 17413571
    [Abstract] [Full Text] [Related]

  • 6. Assessing tumor response to therapy.
    Weber WA.
    J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
    [Abstract] [Full Text] [Related]

  • 7. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
    Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D.
    J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
    [Abstract] [Full Text] [Related]

  • 8. Impact of FDG-PET/CT in the management of lymphoma.
    Baba S, Abe K, Isoda T, Maruoka Y, Sasaki M, Honda H.
    Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
    [Abstract] [Full Text] [Related]

  • 9. PET monitoring of therapy response in head and neck squamous cell carcinoma.
    Schöder H, Fury M, Lee N, Kraus D.
    J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
    [Abstract] [Full Text] [Related]

  • 10. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M.
    J Clin Oncol; 2009 Jul 10; 27(20):3303-11. PubMed ID: 19451443
    [Abstract] [Full Text] [Related]

  • 11. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
    Zhang M, Jiang X, Zhang M, Xu H, Zhai G, Li B.
    J Nucl Med; 2009 Apr 10; 50(4):506-12. PubMed ID: 19289438
    [Abstract] [Full Text] [Related]

  • 12. FDG PET/CT flip flop phenomenon in treated lymphoma of bone.
    Lin EC.
    Clin Nucl Med; 2006 Dec 10; 31(12):803-5. PubMed ID: 17117078
    [Abstract] [Full Text] [Related]

  • 13. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G.
    Eur J Radiol; 2009 Jun 10; 70(3):382-92. PubMed ID: 19406595
    [Abstract] [Full Text] [Related]

  • 14. MRI and PET in monitoring response in lymphoma.
    Rahmouni A, Luciani A, Itti E.
    Cancer Imaging; 2005 Nov 23; 5 Spec No A(Spec No A):S106-12. PubMed ID: 16361125
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
    Tsujikawa T, Otsuka H, Morita N, Saegusa H, Kobayashi M, Okazawa H, Nishitani H.
    Ann Nucl Med; 2008 Jan 23; 22(1):23-30. PubMed ID: 18250984
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. FDG-PET in the clinical management of Hodgkin lymphoma.
    Hutchings M, Eigtved AI, Specht L.
    Crit Rev Oncol Hematol; 2004 Oct 23; 52(1):19-32. PubMed ID: 15363464
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.